Jessica Koach

City College of San Francisco — United States

Medicine · Health Sciences

15h-index1.0kcitations58works8.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(31), Cancer, Hypoxia, and Metabolism(11), Ubiquitin and proteasome pathways(10), interferon and immune responses(7), HER2/EGFR in Cancer Research(6)

Publications58 total

EXTH-117. Bitopic inhibitors of mTORC1 cooperate with inhibitors of mitogen-activated protein kinase kinase to drive cytotoxicity in glioblastoma
Neuro-Oncology·2025Open Access
PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies
Cells·2025Open Access
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma
EJNMMI Research·2024· 5 citedOpen Access
Author Correction: MYC phase separation selectively modulates the transcriptome
Nature Structural & Molecular Biology·2024· 2 citedOpen Access
MYC phase separation selectively modulates the transcriptome
Nature Structural & Molecular Biology·2024· 45 citedOpen Access
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma
Research Square (Research Square)·2024Open Access
Supplementary Figure S6 G-K from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Data from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Information from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S4 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 F-H from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S1 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S3 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S3 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 F-H from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S2A-C from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S3 F-G from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Data from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Belamy B. Cheung(43), Glenn M. Marshall(40), Michelle Haber(33), Murray D. Norris(33), Tao Liu(30), Daniel R. Carter(26), Bing Liu(24), Jessica L. Bell(23), Chelsea Mayoh(22), Michael W. Parker(21), Jayne Murray(20), Jessica K. Holien(20), Giorgio Milazzo(20), Giovanni Perini(20), Hassina Massudi(20), Andrew J. Gifford(19), André Oberthuer(19), Brendan W. Stevenson(19), W. Clay Gustafson(19), Jamie I. Fletcher(19)